Toronto Dominion Bank
ACRV icon

Toronto Dominion Bank’s Acrivon Therapeutics ACRV Stock Holding History

Toronto Dominion Bank’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-41
Closed -$392 – 1575
2023
Q3 		$392 Buy
+41
New +$474 ﹤0.01% 1534

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Toronto Dominion Bank's ACRV Position: Q4 2023 in Review

Toronto Dominion Bank sold out of Acrivon Therapeutics (ACRV) in Q4 2023, closing a stake of 41 shares — an estimated $392 sold.

Toronto Dominion Bank first reported a position in ACRV in Q3 2023 and held it in 1 quarter. The position peaked at $392 in Q3 2023. 42 funds tracked by Wall St. Rank hold ACRV as of Q4 2023.

  • Toronto Dominion Bank reported no remaining Acrivon Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Toronto Dominion Bank sold 41 Acrivon Therapeutics shares in Q4 2023, an estimated $392.
  • Toronto Dominion Bank first reported a position in Acrivon Therapeutics in Q3 2023 and held it in 1 quarter.
  • Toronto Dominion Bank's Acrivon Therapeutics position peaked at $392 in Q3 2023.
  • 42 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2023.

Based on Toronto Dominion Bank's 13F filing for Q4 2023, filed 13 Feb 2024.